Highest-materiality recent filing
Zai Lab Q1 2026 revenue $99.6M (-6% YoY); net loss $51M; zoci shows 62.5% intracranial ORR
Total revenues $99.6M, down 6% YoY; product revenue $95.6M (-10% YoY); ZEJULA fell to $30M from $49.5M.
Zai Lab Q4 total revenue $127.6M (+17% YoY); net loss narrows to $50.4M
Q4 product revenue $127.1M (+17% YoY); ZEJULA $56M (+16%), XACDURO $10.7M (+225%).
Zai Lab Q3 revenue up 14% to $116.1M; loss narrows; revises FY2025 guidance to at least $460M
Product revenue $115.4M (+13% YoY); VYVGART $27.7M, ZEJULA $42.4M, NUZYRA $15.4M.
Zai Lab Q2 revenue grows 9% YoY to $110M; operating loss improves 28%; targets Q4 profitability
Product revenue $109.1M (+9% YoY); VYVGART sales $26.5M (+46% QoQ); ZEJULA $41.0M (down from $45M YoY).
Zai Lab Q1 revenue up 22% to $106.5M; operating loss narrows 20%; on track for Q4 profitability
Product revenue $105.7M (+21% YoY); VYVGART $18.1M, ZEJULA $49.5M, NUZYRA $15.1M.
Zai Lab Q4 2024 revenue $109.1M (+66% YoY); guides FY2025 revenue $560-590M
Total revenues $399.0M for FY2024, up 50% YoY; product revenue $397.6M, up 49% YoY.
Zai Lab updates risks: employee medical fraud probes in China, Optune patent setbacks
Several current/former employees in ZEJULA sales team under criminal investigation by Chinese authorities for alleged medical insurance fraud; individuals detained or under compulsory measures.
Zai Lab Q3 net product revenue rises 47% YoY to $101.8M; KarXT bridging study positive
Net product revenue $101.8M, up 47% YoY; net loss $41.7M ($0.42/ADS loss).
Zai Lab Q2 net product revenue $100.1M (+45% YoY); narrows net loss to $80.3M
Net product revenue $100.1M, up 45% YoY (47% at CER); VYVGART contributed $23.2M vs $0.1M YoY.
Zai Lab Q1 product revenue $87.1M (+39% YoY); net loss $53.5M, VYVGART sales $13.2M
Product revenue $87.1M (+39% YoY; +43% at CER); ZEJULA $45.5M (+7%), VYVGART $13.2M (launch Sep 2023).
Zai Lab FY2023 product revenue $266.7M (+25% YoY); VYVGART launch drives 2024 outlook >$70M
Product revenue $266.7M (+25% YoY; +31% CER); net loss narrowed to $334.6M from $443.3M.
Zai Lab Q3 revenue $69.2M (+22% YoY); launches VYVGART in China, net loss narrows
Product revenue $69.2M, up 22% YoY; VYVGART contributed $4.9M since September launch.
Zai Lab Q2 product rev $68.9M (+45% YoY); VYVGART approved in China; net loss $120.9M
Product revenue $68.9M, up 45% YoY (53% constant currency); driven by ZEJULA $43.0M, Optune $13.7M.
China NMPA approves Zai Lab's VYVGART for generalized myasthenia gravis
NMPA approved VYVGART (efgartigimod alfa) as add-on for anti-AChR+ gMG adults.
TTFields + standard therapies improved median OS from 9.9 to 13.2 months (HR 0.74, p=0.035) in post-platinum metastatic NSCLC.
Zai Lab Q1 product revenue $62.8M, up 36% YoY; net loss narrows to $49.1M
Product revenue $62.8M (+36% YoY); ZEJULA $42.7M (+44% YoY); Optune $13.3M; QINLOCK $1.3M; NUZYRA $5.5M.
Zai Lab Reports Full-Year 2022 Revenue of $215M, Up 49% YoY
Total revenue $215.0M in 2022, a 49.0% increase year-over-year; ZEJULA revenue $145.2M, up 55.2%.
Zai Lab partner Novocure's LUNAR study meets primary overall survival endpoint in stage 4 NSCLC
LUNAR study showed statistically significant and clinically meaningful improvement in overall survival vs standard therapies alone.
Zai Lab Q3 revenue $57.5M (+33% YoY); net loss widens to $161.2M on Seagen payment
Total revenues $57.5M vs $43.1M YoY; net product revenue led by ZEJULA $39.2M.
Zai Lab pays $30M upfront, up to $78M in dev/reg milestones, and up to $185M in sales milestones.
Zai Lab Q2 2022 revenue $48.2M (+31% YoY); net loss narrows; efgartigimod BLA accepted in China
Total revenues $48.2M (Q2 2021: $36.9M); ZEJULA revenue $34.1M (+46% YoY). Net loss $137.9M vs $163.3M.
Zai Lab shareholders approve 2022 Equity Plan and amended Articles for HK dual-primary listing
Shareholders approved 2022 Equity Incentive Plan (97,908,743 shares) conditioned on HKEX dual-primary listing becoming effective.
Zai Lab receives HKSE acknowledgement for dual-primary listing effective June 27, 2022
HKSE acknowledged Zai Lab's application for voluntary conversion from secondary to dual-primary listing.
Zai Lab engages KPMG as US auditor to comply with HFCAA and maintain Nasdaq listing
Engaged KPMG LLP as independent auditor for FY2022, replacing Deloitte.
Zai Lab's NDA for margetuximab accepted by China NMPA for HER2+ breast cancer
NMPA accepted NDA for margetuximab, a HER2-targeted monoclonal antibody, for metastatic HER2+ breast cancer with 2+ prior anti-HER2 therapies.
Zai Lab promotes Harald Reinhart to President and Head of Global Development
Harald Reinhart, M.D., promoted from CMO to President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
NMPA approves Zai Lab's NUZYRA as Category 1 innovative drug for CABP and ABSSSI
NMPA approved NUZYRA (omadacycline) for community-acquired bacterial pneumonia and acute bacterial skin infections.
On May 18, 2026, the Board of Directors of Zai Lab Limited (the “Company”) determined that Mr. Josh Smiley will cease serving as President and Chief Operating Officer of the Company, effective as of May 18, 2026, and his last day of employment with the Company will be May 22, 2026.
On June 11, 2024 , Zai Lab Limited (the “Company”) announced that Dr. Harald Reinhart, President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases, has informed the Company that he has decided to retire, effective June 30, 2024.
Also on July 6, the Company announced that Dr. Chen will be succeeding William Cho, who is stepping down from his role as Chief Financial Officer, effective July 7, 2023.
On July 6, 2023, Zai Lab Limited (the “Company”) announced that it has appointed Dr. Yajing Chen as its Chief Financial Officer, effective July 7, 2023.
On January 7, 2023, the Board of Directors (the “Board”) of Zai Lab Limited (the “Company”) appointed Michel Vounatsos as an independent director, effective immediately.
Dr. Alan Sandler who provided notice that he is resigning from the Company, effective October 28, 2022, to pursue another professional opportunity.
Zai Lab Limited (the “Company”) appointed Joshua Smiley as the Company’s Chief Operating Officer, effective on August 1, 2022
On March 28, 2022, Tao Fu, Chief Strategy Officer of Zai Lab Limited (the “Company”), provided notice to the Company of his resignation from the Company, effective as of the close of business on April 8, 2022.
On March 15, 2022, Zai Lab Limited (the “Company”) announced the appointment of Joshua Smiley as the Company’s Chief Operating Officer.
On December 22, 2021, Zai Lab Limited (the “Company”) announced the promotion of Harald Reinhart, M.D., from his current role as Chief Medical Officer to President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases.
On November 19, 2021 (U.S. Eastern Time), the Board of Directors (the “Board”) of Zai Lab Limited (the “Company”) appointed Richard Gaynor as an independent director, effective immediately.
On October 13, 2021 (U.S. Eastern Time), the Board of Directors (the “Board”) of Zai Lab Limited (the “Company”) appointed Scott W. Morrison as an independent director, effective immediately.
Max materiality 0.85 · Median 0.65 · Most common event earnings